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CapsidCryoelectron microscopy images of HPV16 pseudovirions (PsV) depict that each pentamer of L1 can be
occluded with a monomer of L2. Further research suggests that an N-terminal external loop of L2 exists,
which is the target of neutralizing and cross-neutralizing antibodies. Here we show that N-terminal L2
cysteine residues, Cys22 and Cys28, have overlapping and independent structural roles, which affect both
early- and late-stage assembly events. Substitution of either cysteine residue enhances infectivity markedly
in comparison to wild-type HPV16. However, only Cys22Ser 20-day virions become nearly as stable as wild
type. In addition, Cys22Ser, and Cys22,28Ser 20-day virions have lost their susceptibility to neutralization by
anti-L2 antibodies, whereas Cys28Ser 20-day virions remain partially susceptible. These results suggest that
Cys28 is necessary for late-stage stabilization of capsids, while Cys22 is necessary for proper display of L2
neutralizing epitopes.
© 2009 Elsevier Inc. All rights reserved.Introduction
Human papillomavirus (HPV) virions contain a single, circular
dsDNA genome of approximately 8 kb, which associates with histones
to form a chromatin-like structure (Conway and Meyers, 2009;
Doorbar, 2005; Longworth and Laimins, 2004). This minichromosome
is packaged within a nonenveloped, icosahedral capsid composed of
72 pentamers of themajor capsid protein L1 and an unknown number
of the minor capsid protein L2 (Buck et al., 2008; Conway and Meyers,
2009; Finnen et al., 2003; Trus et al., 1997). High-resolution images of
native bovine papillomavirus 1 (BPV1) and HPV16 pseudovirions
(PsV) suggest that pentamers of L1 can be occluded with a monomer
of the minor capsid protein L2 (Buck et al., 2008; Trus et al., 1997).
Critical to the production of an effective second-generation
vaccine, an N-terminal “external loop” of L2 exists, which can be the
target of neutralizing and cross-neutralizing antibodies (Conway et
al., in press; Day et al., 2008a; Gambhira et al., 2007; Kondo et al.,
2007; Liu et al., 1997). Speciﬁcally, peptides generated from L2
residues 17–36 have been shown to elicit a wide-ranging cross-
neutralizing antibody response (Gambhira et al., 2007). Two N-
terminal L2 cysteines, Cys22 and Cys28, are conserved among all
mammalian and avian papillomaviruses, and recent work utilizing
HPV16 quasivirions (QV) has depicted the presence of a permanent
disulﬁde bond between Cys22 and Cys28—suggestive of the structural
relevance of these residues (Campos and Ozbun, 2009). Consideringll rights reserved.the proximity of Cys22 and Cys28 to the cross-neutralizing 17–36
epitope, we hypothesized that Cys22 and/or Cys28 might play a role
in structural rearrangements of L2, which facilitate the presentation of
cross-neutralizing epitopes contained within the L2 external loop.
Previously, we have shown that organotypic culture-derived na-
tive virions, in the context of the complete papillomavirus life cycle,
utilize a tissue-spanning redox gradient, which facilitates multiple
redox-dependent assembly and maturation-like events over the
course of many days (Conway and Meyers, 2009). We showed that
stability and speciﬁc infectivity of 20-day virions increases over 10-
day virions, that 20-day virions become more susceptible to
neutralization than 10-day virions, and that both viral DNA encapsi-
dation and infectivity of HPV-infected tissues are redox-dependent in
that they can be manipulated via the treatment of organotypic tissues
with oxidized glutathione (GSSG), which is temporally and concen-
tration-dependent (Conway and Meyers, 2009). These data suggest
that papillomavirus virions undergo a very long assembly process
within tissue, which is dependent on disulﬁde bond formation.
Here, we show that N-terminal HPV16 L2 cysteine residues,
Cys22 and Cys28, have overlapping and independent structural roles,
which can be temporally distinguished. In our system, Cys28Ser
10-day and 20-day virions are more physically fragile than wild
type, while Cys22Ser 20-day virions become nearly stable as wild
type, suggesting that Cys28 is involved in late-stage stabilization of
virions. In addition, Cys22Ser and Cys22,28Ser 20-day virions have
lost their susceptibility to neutralization by anti-L2 antibodies,
whereas Cys28Ser 20-day virions remain susceptible to neutraliza-
tion. These results suggest that Cys22 plays a major role and Cys28 a
minor role in the display of N-terminal cross-neutralizing epitopes.
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either cysteine residue for serine in HPV16 organotypic culture-
derived virions enhanced infectivity markedly over wild type
(Campos and Ozbun, 2009). In addition, speciﬁc infectivity of 20-
day mutant virions increased over their 10-day mutant counterparts
more than wild type, suggesting that Cys22 and Cys28 both hinder a
transitional phase involved in the enhancement of speciﬁc infectivity
in 20-day wild-type virions (Campos and Ozbun, 2009; Conway and
Meyers, 2009).
Results
Establishment of cell lines infected with HPV16 L2 mutants
To develop producer cell lines that can synthesize organotypic
culture-derived native virions from differentiating epithelia, primary
human foreskin keratinocytes (HFKs) were electroporated with
linearized wild-type and site-directed mutagenized HPV16(114/B)
DNA (Kirnbauer et al., 1993). The recircularization and maintenance
of episomal HPV16 viral genomes for representative HPV16 L2
Cys22Ser, Cys28Ser, and Cys22,28Ser cell lines can be seen in Fig. 1A.
Data for wild-type HPV16 cell lines have been published previously
(Conway et al., in press; McLaughlin-Drubin, Christensen, and
Meyers, 2004). The total number of episomal copies per cell was
less in mutant cell lines (∼10–200 copies/cell) than the wild-type
cell line utilized (N1000 copies/cell). We do not believe that the
lower copy numbers observed in the mutant cell lines are signiﬁcant
regarding productivity of tissues as previous reports have suggested
that copy number does not directly correlate with the titer of HPV-
infected organotypic tissues (McLaughlin-Drubin, Christensen, and
Meyers, 2004; McLaughlin-Drubin et al., 2003; Meyers, Mayer, and
Ozbun, 1997). In addition, the use of viral genome equivalents (vge)
and/or detection of the major capsid protein via Western blot
analysis allows for the analysis of the relative speciﬁc infectivity (i.e.,
vge or protein to infectivity ratio) of individual virions produced by
HPV-infected organotypic tissues, which eliminates potential differ-
ences in tissue productivity (Conway et al., in press). For each
mutant genome, multiple episomal DNA-containing cell lines were
produced and utilized in experiments to control for PCR ﬁdelity
during the mutagenesis protocol. In addition, L2 ORFs were
sequenced to verify the existence of the intended mutation and the
absence of erroneous mutations in all cases. Stable cell lines were
then allowed to grow as stratiﬁed and differentiated epithelial
tissues in organotypic culture (Fig. 1B).Fig. 1. Episomal maintenance of mutant viral genomes and stratiﬁcation of organotypic
with Cys22Ser, Cys28Ser, and Cys22,28Ser substitutions. Uncut (U) and single BamHI cut
per 5 μg of total genomic DNA. (B) Hematoxylin and eosin staining of parafﬁn-embedded
tissue.Infectivity of L2 mutant virions
To determine if substitution of L2 cysteines altered infectivity of
crude viral preps (CVPs) or speciﬁc infectivity of virions (i.e., vge to
infectivity ratio), we performed duplex RT-qPCR-based infectivity
assays on 10- and 20-day CVPs made from wild-type and mutant-
infected organotypic tissues. All CVPs were benzonase treated to digest
nonencapsidated and susceptible viral genomes within the CVP
(Conway and Meyers, 2009). The completeness of the benzonase
reaction was veriﬁed by assessing the digestion of 1 μg of spike HPV16
DNA under identical conditions (data not shown). Surprisingly,
Cys22Ser and Cys28Ser CVPs were consistently much more infectious
than wild type, with 10-day mutant CVPs averaging 100-fold more
E1^E4 expression (Fig. 2A) and 20-day mutant CVPs averaging 10,000-
and 1000-fold more E1^E4 expression, respectively (Fig. 2B). Ten- and
twenty-day Cys22,28Ser CVPs were more infectious, with 10- and
1,000-fold more E1^E4 expression than wild type, respectively (Figs.
2A, B). These results suggest that either more virions are produced
within Cys22Ser, Cys28Ser, and Cys22,28Sermutant organotypic tissues
or each individual mutant virion is more infectious than wild type.
To quantify the total number of vge within each CVP, we utilized a
qPCR-based DNA encapsidation assay to detect endonuclease-resis-
tant genomes as described previously and in the Materials and
methods section (Conway et al., in press; Holmgren et al., 2005;Wang
et al., 2009). Brieﬂy, 10 μl aliquots of CVPs were Hirt extracted for viral
nucleic acid and extracted DNA was run alongside a standard curve
made from 10-fold dilutions of HPV16 DNA in a SYBR-green-based
qPCR reaction. As the total number of viral genomes within each point
on the standard curve was known (based on the weight of an
individual nucleotide and the size of the HPV16 genome), values
obtained from experimental samples were back calculated and
converted to total genomes per raft. Because of the low productivity
of organotypic culture in producing HPV virions in comparison to
techniques that produce HPV virus-like particles (VLPs), pseudovir-
ions (PsV), and quasivirions (QVs), in addition to high background
cellular keratin bands during Western blot analyses, vge is the most
quantitative method for normalization at this time (Buck et al., 2004;
Conway andMeyers, 2009; Pyeon, Lambert, and Ahlquist, 2005). At 10
days, Cys22Ser CVPs contained 4.5%±1.3%, Cys28Ser CVPs contained
7.5%±1.5%, and Cys22,28Ser CVPs contained 1.6%±0.5% of the total
number of encapsidated genomes contained within wild-type CVPs,
with included standard error values (Fig. 3A). Such decreases in
encapsidated genomes found in mutant CVPs suggest that the ob-
served increase in infectivity (Figs. 2A, B) in comparison towild type iscultures. (A) Southern blot hybridization of HPV16(114/B)-infected HFK cell lines
(B) episomal genomes are shown in addition to 1, 10, and 100 viral genome copies
, 10-day wild-type (WT), Cys22Ser-, Cys28Ser-, and Cys22,28Ser-infected organotypic
Fig. 2. (A–B) Relative RT-qPCR-based infectivity analysis of 10- and 20-day wild-type, Cys22Ser, Cys28Ser, and Cys22,28Ser crude viral preps (CVPs) and (C) relative speciﬁc
infectivity (vge-to-infectivity ratio) of wild-type and mutant virions. Fifty microliters of (A) 10- or (B) 20-day wild-type or mutant CVPs were diluted 1:10 in a total volume of
500 μl HaCaT media and utilized to infect 5×105 HaCaT cells. RNA was harvested and relative E1^E4 expression was detected via duplex RT-qPCR and plotted with 10- and
20-day wild-type infections set to 1.0. To calculate speciﬁc infectivity of virions (C), vge values obtained in Figs. 3A, B were utilized to normalize RT-qPCR-based infectivity assay
data in panels A, B. Ten-day wild-type infections were set to 1.0. Experiments were performed in triplicate with an incorporated±standard error of the mean.
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vge yields correlate with the destabilization of capsids, Cys428Ser
mutant-infected tissues were generated as described for the L2
mutants above. Substitutions of Cys428 have been shown to be
destabilizing in virus-like particles (VLPs), PsV, and organotypic
culture-derived virions (Buck et al., 2005; Conway et al., in press;
Ishii, Tanaka, and Kanda, 2003; Li et al., 1998). The Cys428Ser mutant
stable cell line utilized contained 100 episomal copies/cell and grew
into fully stratiﬁed and differentiated epithelial tissues (Conway and
Meyers, 2009). As 10-day Cys428Ser mutant CVPs contained 1.2%±
0.3% of the total number of encapsidated genomes contained within
wild-type CVPs, it supports that substitution of L2 cysteine residues
destabilize papillomavirus particles (Fig. 3A). At 20 days, Cys22SerFig. 3. Encapsidated genomes within benzonase-treated, (A) 10- and (B) 20-day wild-
type, Cys22Ser, Cys28Ser, Cys22,28Ser, and Cys428Ser crude viral preps (CVPs). Equal
aliquots of three wild-type andmutant CVPs were incubated with Proteinase K and SDS
for 2 h, spiked with 6% 2-ME and boiled for 10 min prior to extracting endonuclease
resistant genomes. Viral genomes were plotted against a standard curve using SYBR
green-based chemistry. All experiments were performed in triplicate with an incor-
porated standard error of the mean.CVPs contained 73.0%±2.0%, Cys28Ser CVPs contained 4.2%±0.76%,
and Cys22,28Ser CVPs contained 1.5%±0.06% of the total number of
encapsidated genomes contained within 20-day wild-type CVPs
(Fig. 3B). The dramatic increase in observed encapsidated genomes
within 20-day Cys22Ser CVPs and the lack of increase in Cys28Ser and
Cys22,28Ser CVPs suggest that either the loss of Cys22 and
consequent disulﬁde bonding stabilizes 20-day virions or Cys28 is
critical for late-stage encapsidation of genomes and/or stabilization
of capsids via a novel disulﬁde interaction.
In Fig. 2C, vge values obtained in Figs. 3A, B were utilized to norm-
alize RT-qPCR-based infectivity assay data in Figs. 2A, B. Taking vge
into consideration, enhanced speciﬁc infectivity was observed for 10-
day Cys22Ser, Cys28Ser, and Cys22,28Ser virions, at 2868-, 3608-, and
346-fold more infectious than wild type, respectfully. At 20 days, the
speciﬁc infectivity of mutant virions all became markedly more infec-
tious than wild type in addition to their 10-day mutant counterparts,
with Cys22Ser virions 27,026-fold, Cys28Ser virions 43,965-fold, and
Cys22,28Ser virions 128,688-fold more infectious than 10-day wild-
type virions. As speciﬁc infectivity of 20-day wild-type virions is en-
hanced, approximately 2.2-fold over 10-day wild-type virions, 20-day
Cys22Ser, Cys28Ser, and Cys22,28ser virions were 12,284-, 19,984-,
and 58,494-fold more infectious than 20-day wild-type virions.
Stability of L2 mutant virions
When we performed our DNA encapsidation assay on 10- and 20-
day wild-type and mutant CVPs, we did not detect an increase in the
amount of endonuclease-resistant genomes in mutant CVPs, which
would correlate with their increased infectivity titers (Figs. 3A, B).
Instead we detected marked decreases in endonuclease-resistant
genomes withinmutant CVPs. We interpret these results to mean that
either fewer particles are made in mutant tissues or that mutant
virions are susceptible to endonuclease digestion and are thus more
fragile than wild-type virions. Both explanations suggest that, even
thoughmore fragile and less apt to form a proper capsid, virions made
with mutant L2 proteins are more infectious than wild type. It is also
possible that the cysteine mutations lead to the production of
particles that are much more resistant to chemical reduction, which
would lead to the lack of detection of endonuclease-resistant
genomes in our DNA encapsidation assay.
To further assess the stability of wild-type and mutant virions, we
fractionated CVPs on Optiprep step gradients and infected HaCaT cells
Fig. 4. Stability of (A) 10- and (B) 20-day wild-type, Cys22Ser, Cys28Ser, Cys22,28Ser,
and Cys428Ser virions. (A) 10-day, benzonase-treated, wild-type, Cys22Ser, Cys28Ser,
Cys22,28Ser, and Cys428ser crude viral preps (CVPs) were Optiprep-fractionated and
fractions were inoculated into HaCaT cells at a dilution of 1:10. Fraction 1 represents the
top of the gradient, while fraction 11 represents the bottom. Infectivity was assessed via
RT-PCR by amplifying E1^E4 in tandem with the PCR control, β-actin. (B) Twenty-day,
benzonase-treated, wild-type, Cys22Ser, Cys28Ser, Cys22,28Ser, and Cys428ser crude
viral preps (CVPs) were Optiprep fractionated and fractions were inoculated into HaCaT
cells at a dilution of 1:10. Fraction 1 represents the top of the gradient, while fraction 11
represents the bottom. Infectivity was assessed via RT-PCR by amplifying E1^E4 in
tandem with the PCR control, β-actin.
Fig. 5.Neutralization of 10- and 20-daywild-type, Cys22Ser, Cys28Ser, and Cys22,28Ser crude
P56/75) and (B)monoclonal antibodies (S910-1 andRG-1). Fiftymicroliters of each CVPwas d
500 μl of HaCaT media. Neutralization reactions commenced for 1 h at 37 °C prior to infectio
relative E1^E4 expression via duplex RT-qPCR. No antibody controls (–) were set to 1.0. All ex
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to assay for infectivity via RT-PCR (Figs. 4A, B). Optiprep gradient
fractionation of HPV virions has been reported to destabilize capsids
(Buck et al., 2004; Conway and Meyers, 2009). While infectivity was
detected in fractions 6–8 from 10-day wild-type CVPs, infectivity was
not detected in any fraction from 10-day mutant CVPs (Fig. 4A). To
verify that loss of infectivity was due to fragility of capsids, CVPs made
from 10-day organotypic tissues capable of synthesizing the HPV16 L1
mutant, Cys428Ser, were Optiprep fractionated and assayed for
infectivity (Ishii, Tanaka, and Kanda, 2003; Li et al., 1998; Sapp et
al., 1998) (Fig. 4A). Infectivity was also not observed in Optiprep-
fractionated 10-day Cys428Ser CVPs, suggesting that the L2 mutations
do perturb the structure of the virion leading to a more fragile
phenotype (Fig. 4A). However, like fractions from 20-day wild-type
CVPs where infectivity is observed in fractions 6–7, infectivity can be
detected in 20-day Cys22Ser CVP fractions 5–8 (Fig. 4B). Along with
the DNA encapsidation assay results in Figs. 2A, B, these results
suggest that Cys22Ser virions are more fragile than wild type at 10
days but become more stable at 20 days. Cys28Ser and Cys22,28Ser
virions remain fragile at both time points, suggesting that Cys28 plays
a crucial role in late-stage stability of papillomavirus virions whereas
Cys22 plays a role in virion stability at all stages of papillomavirus
assembly.
Neutralization of L2 mutant virions with anti-L2 Abs
Because of the proximity of HPV16 N-terminal cysteines to cross-
neutralizing epitopes, we sought to determine whether Cys22Ser,
Cys28Ser, and Cys22,28Ser mutations would alter the wild-type
neutralization proﬁle. Neutralizing activities of anti-HPV16 L2 anti-
sera were measured by inhibition of infection of HaCaT cells with
wild-type and mutant HPV16 (Figs. 5A, B) (Gambhira et al., 2007;
Kondo et al., 2007).viral preps (CVPs)with (A) anti-L2 “external loop”polyclonal (anti-P14/27 #2 and anti-
iluted 1:10with (+) orwithout (–) a 1:100 dilution of each antibody in a total volume of
n of 5×106 HaCaT cells. RNA was harvested and infectivity was assessed by measuring
periments were performed in triplicatewith an incorporated standard error of themean.
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Cys22Ser, Cys28Ser, and Cys22,28Ser CVPs and then inoculated to
HaCaT cells. This concentration of antisera was near the highest
concentration tested in previous studies (Gambhira et al., 2007;
Kondo et al., 2007). Forty-eight hours later, duplex RT-qPCR-based
infectivity assays were utilized to detect relative expression of E1^E4.
The vge/cell added for neutralizations of 10-day CVPs is as follows:
34,338 for wild type, 1560 for Cys22Ser, 2,570 for Cys28Ser, and 546
for Cys22,28Ser. The vge/cell added for neutralizations of 20-day CVP
is as follows: 49,353 for wild type, 36,034 for Cys22Ser, 2062 for
Cys28Ser, and 719 for Cys22,28Ser. The wide range of wild-type and
mutant vge/CVP prohibited us from performing the neutralization
assay utilizing equal vge numbers. Because of the low productivity of
organotypic culture in producing HPV virions, in addition to the
severe cross-reactivity between antibodies and cellular keratin, vge
remains the most quantitative method for normalization (Conway
and Meyers, 2009). As shown in Figs. 5A, B, wild-type HPV16 can only
be effectively neutralized with a panel of anti-HPV16 L2 antibodies:
anti-P14/27 #2 (AA 14–27), anti-P56/75 #1 (AA 56-75), #S910-1 (AA
1-88), and RG-1 (AA 17-36) when virions have matured within
tissue for 20 days (Conway et al., in press; Gambhira et al., 2007;
Kondo et al., 2007). Similar to wild type, 10-day Cys22Ser, Cys28Ser,
and Cys22,28Ser mutant virions are not effectively neutralized (Figs.
5A, B). Twenty-day Cys22Ser and Cys22,28Ser virions are also not
effectively neutralized even when fewer vge/cell are neutralized as
compared to wild type (Figs. 5A, B). In addition to the failure of
antibodies to neutralize, signiﬁcant increases in infectivity were
observed after addition of #S910-1 to 10- and 20-day Cys22Ser virions
andwhen RG-1was added to 20-day Cys22Ser virions. In contrast, 20-
day Cys28Ser virions partially retained susceptibility to neutralization
by anti-P14/27 #2, and anti-P/56/75 #1 as compared to wild-type
(Figs. 5A, B). These antibody neutralization studies suggest that Cys22
is important in late-stage exposure of cross-neutralizing epitopes on
the L2 external loop. Cys28 appears to play a minor role.
Discussion
While major capsid protein L1 is sufﬁcient to produce virus-like
particles (VLPs) in vitro, the minor capsid protein L2 has a growing
repertoire of structural and functional roles not limited to DNA
encapsidation, assembly, stabilization, entry, and transit of genomes
into the nucleus (Bordeaux et al., 2006; Bossis et al., 2005; Buck et al.,
2005; Finnen et al., 2003; Ishii et al., 2005; Richards et al., 2006; Zhou
et al., 1994). Recent cryoelectronmicroscopy image reconstructions of
HPV16 pseudovirions (PsV) corroborate previous studies that depict
L2 localization within the inner conical hollow of L1 pentamers (Buck
et al., 2008; Trus et al., 1997). While the general location of L2 within
the capsid appears understood, many aspects of the protein are
unknown or controversial such as the total number of L2 proteins per
virion, detailed structural information about L2 and how it interacts
with its neighboring L1 pentamers, and functional aspects regarding
L2 structural rearrangements, which allow the L2 external loop to
facilitate neutralizing epitope recognition, furin cleavage, and inter-
action with cellular and extracellular receptors (Day et al., 2008a; Day
et al., 2008b; Liu et al., 1997; Richards et al., 2006; Yang et al., 2003).
Many studies have reported domains of L2 that interact with L1
(Buck et al., 2008; Finnen et al., 2003; Lowe et al., 2008; Touze et al.,
2000). L2 only appears to interact with capsomeres of L1 and not
intact VLPs, suggesting that L2 and L1 co-assemble (Finnen et al.,
2003). During differentiation, such co-assembly would require a
regulated process mediated by interactions between these two pro-
teins. The C-terminus of both BPV1 and HPV11 L2 has L1 interacting
domains, in addition to an internal L1 interacting domain in BPV1 L2
(Touze et al., 2000). Recent research has also concluded that the N-
terminus of L2 may interact with L1, although a physical interaction
has yet to be validated (Buck et al., 2008; Lowe et al., 2008). Since L2enhances assembly of L1 capsomeres in the absence of disulﬁde
bonding, hydrophobic interactions between L2 and L1 are most likely
to initiate early assembly events (Ishii et al., 2005). In the context of
stratiﬁed epithelial tissue, these early assembly events would appear
to occur in the chemically reducing environment of the suprabasal
compartment, which would necessitate hydrophobic rather than
disulﬁde interactions (Conway and Meyers, 2009).
The individual domains of L2 involved in binding to L1 at various
time points during the assembly process are not known. However,
recent advances in VLP, and PsV technology have found that a
maturation step is required for stabilization of synthetic papillomavi-
rus particles to make them appear more native virus-like (Buck et al.,
2005; Mach et al., 2006). Themorphological change from immature to
mature PsV opens the possibility of temporal interactions between L2
and L1 (Buck et al., 2005). Such a maturation step is also evident is
organotypic culture-derived native virions as virions extracted from
20-day-old tissues have a higher speciﬁc infectivity, are more stable,
and become more susceptible to neutralization than virions extracted
from 10-day-old tissues (Conway and Meyers, 2009).
Temporal changes in L2 structure have been elucidated through
the neutralization of HPV16 PsV with the anti-L2 “external loop”
monoclonal antibody RG-1 (AA 17–36) whereby mature PsV are only
effectively neutralized by this antibody post-cell adsorption (Day et
al., 2008a). Reports have also shown that N and C-terminal L2 epitope
tags are not accessible to antibody binding until after hours of cell
binding (Day et al., 2004). In addition, it was reported by our
laboratory that effective neutralization of HPV16 organotypic culture-
derived virions via RG-1 only occurs when virions are extracted from
20-day-old tissue (Conway and Meyers, 2009). These results indicate
that L2 conformational changes can occur both during capsid
assembly and at the cell surface (Conway et al., in press; Day et al.,
2004; Day et al., 2008a; Richards et al., 2006).
Hypothesizing that L2 cysteines may be involved in the external-
ization of neutralizing and cross-neutralizing epitopes, and perhaps
temporal interactions with L1, we substituted each cysteine for serine,
making cell lines competent in synthesizing mutant native virions in
organotypic culture. Surprisingly, all mutated genomes led to the
production of 10- and 20-day virions with a higher speciﬁc infectivity
than wild-type HPV16. This was in contrast to work with mature
HPV16 quasivirions (QV) whereby identical amino acid substitutions
led to the production of noninfectious virions (Campos and Ozbun,
2009). This discrepancy may underscore subtle differences in capsid
structure between papillomavirus particles produced in monolayer
cell culture versus in differentiating epithelial tissue. However,
infectivity of the mutant QV was only assessed after Optiprep
fractionation rather than from crude 293TT cell lysates (Campos and
Ozbun, 2009). In our hands, infectivity of 10-daymutant virions is also
lost after Optiprep fractionation and surprisingly restored in 20-day
Cys22Ser virions. This suggests thatmature QV are as fragile as our 10-
day virions. Different virion extraction protocols may also play a role
as monolayer culture-derived particles are harvested via detergent
lysis, while organotypic culture-derived particles are harvested via
salt extraction. We predict that such an increase in speciﬁc infectivity
of these mutant virions may be due to an enhanced presentation of
the N-terminal furin cleavage site or through the induced fragility of
the virions which may lead to more effective release of viral genomes
post-entry (Day et al., 2008a; Richards et al., 2006).
The proximity of Cys22 and Cys28 to one another might lead to the
hypothesis that these residues form a critical disulﬁde bondwith each
other. Recent biochemical analyses of mature HPV16 QV attest to a
disulﬁde linkage between Cys22 and Cys28 (Campos and Ozbun,
2009). Our data suggest that a permanent disulﬁde bond does not
exist between Cys22 and Cys28 since differential phenotypes are
observed in 20-day mutant virions regarding their stability and
susceptibilities to neutralization via anti-L2 neutralizing antibodies. It
appears that Cys28Ser and Cys22,28Ser virions are more physically
300 M.J. Conway et al. / Virology 393 (2009) 295–303fragile than wild-type HPV16 at all time points, suggesting that Cys22
is insufﬁcient to stabilize the capsid at 20 days. In contrast, Cys22Ser
virions are more physically fragile than wild-type HPV16 at day 10;
however, at day 20, Cys22Ser virions regain their stability, suggesting
that Cys28 may play a role in late-stage stabilization of the capsid. A
scenario can be visualized incorporating previous ﬁndings where
Cys22 and Cys28 play a role in early stabilization of the capsid,
perhaps through a critical disulﬁde interaction (Campos and Ozbun,
2009). At a later time point, however, Cys22 is dispensable for capsid
stabilization and Cys28 becomes critical (Fig. 6). This model suggests
that mature QV lack a conformational capsid rearrangement that only
occurs in virions derived from fully differentiated epithelial tissue.
The location at which the L2 external loop extrudes from the
capsid is, at this point, unknown. Analysis of the inner conical hollow
of an HPV16 L1 pentamer depicts a single L1 cysteine residue, which
may be in an opportune location to temporally interact with L2
cysteines during capsid assembly and maturation (Chen et al., 2000).
While previous examinations into L1–L2 disulﬁde interactions failed
to yield concrete evidence that such bonding occurs, it is tempting to
suggest that Cys28 may temporally isomerize with Cys145 during
capsid assembly (Doorbar and Gallimore, 1987).
Neutralization studies also suggest that Cys22 and Cys28 may play
a role in the architecture of the cross-neutralizing epitope-containing
L2 “external loop”. While 20-day wild-type HPV16 virions are
efﬁciently neutralized by many anti-L2 external loop antibodies, 20-
day Cys22Ser, and Cys22,28Ser mutant virions are resistant to
efﬁcient neutralization, suggesting that their L2 epitopes are not
available to these antibodies. Twenty-day Cys28Ser virions remain
susceptible to partial neutralization. This result suggests that while
Cys22 is not important for stabilization of the capsid at 20 days, it
appears to modulate the accessibility of neutralizing epitopes on the
L2 external loop.
These genetic andmolecular analyses of L2 mutant virions serve to
provide a framework for further detailed structural studies of
papillomavirus capsid interactions. Since the atomic resolution of L2
from native virions and the L2 “external loop” from L1/L2 HPV16 PsV
has not been solved, it is imperative that genetic and biochemical
research be performed in tandem in order to elucidate the many roles
of L2 in the papillomavirus life cycle.Fig. 6. Hypothetical model of HPV16 L2 externalization through the inner conical
hollow of an L1 pentamer. (A) Cys22 and Cys28 are linked via a disulﬁde bond (black
bar) in 10-day native virions forming a hairpin structure. (B) Cys28 and an unknown L1
cysteine residue (black circle) are linked via a disulﬁde bond (black bar) which
stabilizes 20-day capsids.Materials and methods
Mutagenesis
pBSHPV16(114/B) DNA, a generous gift from M. Dürst, was uti-
lized as a template for site-directed mutagenesis using Strategene's
Quikchange II XL Site-Directed Mutagenesis Kit (Kirnbauer et al.,
1993). The protocol utilized a two-step strategy that employed PCR
with the PfuUltra high-ﬁdelity DNA polymerase, and subsequent DpnI
digestion. Following transformation and selection of the mutant
amplimers into XL10 Ultracompetent Escherichia coli cells (Strata-
gene, La Jolla, California), we controlled for polymerase ﬁdelity by
extracting plasmid DNA from many isolated bacterial clones and
sequencing the L1 ORF of each clone to verify correct incorporation of
nucleotide substitutions and the absence of spurious mutations
elsewhere in the L1 ORF. Multiple mutant viral genomic clones con-
taining correctly mutagenized sequences were isolated and utilized in
subsequent experimentation. To create a full-length, HPV16(114/B)
genome with a Cys428Ser substitution, the two complimentary oli-
gonucleotides, forward 5′GTAACCCAGGCAATTGCTTCTCAAAAAC-
ATACACCTCC3′ and reverse 5′GGAGGTGTATGTTTTTGAGAAGCAA-
TTGCCTGGGTTAC3′, were used with the change of G to C at
nucleotide 6917. Cysteines were substituted for the most prevalent
serine codon (TCT) in the HPV16(114/B) L1 ORF. To create a full-
length, HPV16(114/B) genome with a Cys22Ser substitution, the two
complimentary oligonucleotides, forward 5′CTACCCAACTTTATAA-
AACATCTAAACAGGCAGGTACATGTCC3′ and reverse 5′GGACATGTAC-
CTGCCTGTTTAGATGTTTTATAAAGTTGGGTAG3′, were used with the
change of GC to CT at nucleotide 4300. To create a full-length, HPV16
(114/B) genome with a Cys28Ser substitution, the two complimen-
tary oligonucleotides, forward 5′CAAACAGGCAGGTACATCTCCACCT-
GACATTATAC3′ and reverse 5′GTATAATGTCAGGTGGAGATGTACCTG-
CCTGTTTG3′, were used with the change of G to C at nucleotide 4318.
To create a full-length, HPV16(114/B) genome with a Cys22,28Ser
substitution, a full-length, HPV16(114/B) genome containing the
Cys22Ser substitution, which was veriﬁed by sequencing, was utilized
as a template and the two complimentary oligonucleotides, forward
5′CTAAACAGGCAGGTACATCTCCACCTGACATTATAC3′ and reverse
5′GTATAATGTCAGGTGGAGATGTACCTGCCTGTTTAG3′, were used
with the change of GC to CT and G to C at nucleotides 4300 and
4318, respectively. Cysteines were substituted for the most prevalent
serine codon (TCT) in the HPV16(114/B) L2 ORF.
Keratinocyte cultures and electroporation
Primary human foreskin keratinocytes (HFKs) were isolated from
newborn circumcision as described previously (McLaughlin-Drubin
et al., 2003). Brieﬂy, keratinocytes were grown in 154 medium
(Cascade Biologics, Inc., Portland, OR) supplemented with Human
Keratinocyte Growth Supplement Kit (Cascade Biologics, Inc.). For
electroporations, 30 μg of wild-type or mutant pBSHPV16(114/B)
DNAwas digested with BamHI, linearizing the viral DNA at nucleotide
6151 in L1 and separating it from the vector sequence. Primary human
foreskin keratinocytes (HFKs) were electroporated with the pre-
pared DNA as described previously (McLaughlin-Drubin et al., 2003;
Meyers et al., 1992). For mutant genomes, multiple clones obtained
after mutagenesis were utilized to establish stable cell lines to control
for PCR ﬁdelity. Following electroporation, HPV16-positive cell lines
were selected via immortalization as compared to HFKs that were
mock transfected. Multiple stable cell lines were obtained for each
wild-type and mutant construct.
Southern blot hybridization
Total cellular DNA was isolated as previously described (Meyers et
al., 1992). Brieﬂy, 5 μg of total cellular DNA was digested with BamHI,
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rated by 0.8% agarose gel electrophoresis and transferred onto a
GeneScreen Plus membrane (New England Nuclear Research Pro-
ducts, Boston, MA) as previously described (Smith, Campos, and
Ozbun, 2007). Hybridization of the membrane utilized an HPV16-
speciﬁc, whole genomic probe as previously described. (Meyers et al.,
1992).
Organotypic “raft” cultures
Immortalized HFK lines which stably maintained wild-type and
mutant episomal HPV16 DNAwere grown in monolayer culture using
E medium in the presence of mitomycin C-treated J2 3T3 feeder cells
(Meyers et al., 1992). Raft tissues were grown as previously described
(McLaughlin-Drubin and Meyers, 2005; McLaughlin-Drubin et al.,
2003; Meyers et al., 1992). Brieﬂy, HPV16-containing HFK lines were
seeded onto rat tail type-1 collagen matrices containing J2 3T3 feeder
cells not treated with mitomycin C. After epithelial attachment to the
collagenmatrices and growth to conﬂuence, matrices were lifted onto
stainless steel grids. Once lifted to the air–liquid interface, epithelial
raft cultures were fed by diffusion from underneath with E medium,
which lacked epidermal growth factor (EGF) and was supplemented
with 20 mM 1,2-dioctanoyl-sn-glycerol (C8:0, Sigma Chemical, St.
Louis, MO). Raft cultures were allowed to stratify and differentiate for
10, 15, and 20 days.
Histology and immunohistochemical staining
Raft cultures grown for 10 and 20 days were harvested, ﬁxed in
10% neutral buffered formalin, and embedded in parafﬁn. Four-
micrometer sections were cut and stained with hematoxylin and
eosin as previously described (Meyers et al., 1992).
HPV isolation
For Optiprep fractionation, RT-PCR-, RT-qPCR-, and qPCR-based
DNA encapsidation assays, 3-raft virus preps were prepared by
dounce homogenization in 500 μl Benzonase buffer (0.05 M Na-
phosphate [pH 8.0], 2 mM MgCl2). Homogenizers were rinsed with
250 μl Benzonase buffer. 1 μl Benzonase (Sigma) was added to 499 μl
of crude virus preps and incubated at 37 °C for 1 h. Then crude virus
preps were brought to 1 M NaCl by adding 130 μl ice-cold 5 M NaCL.
Crude virus preps were gently vortexed and then centrifuged at 4 °C
for 10 min at 10,500 rpm in a microcentrifuge. Virus-containing
supernatants were reserved as virus preps.
Optiprep puriﬁcation of virions
Optiprep puriﬁcation was performed as described previously
(Buck et al., 2004; Gambhira et al., 2007). Brieﬂy, 27%, 33%, 39%
Optiprep gradients were produced by underlayering. Gradients were
allowed to diffuse for 1 to 2 h at room temperature. Then 600 μl of
clariﬁed benzonase-treated virus preps were layered on top of the
gradient. Tubes were then centrifuged in a SW55 rotor (Beckman) at
234,000×g for 3.5 h at 16 °C. After centrifugation, 11–500 μl fractions
were carefully collected from the top of each tube.
Endpoint RT-PCR infectivity assays
The HPV16 infectivity studies were based on an in vitro system
described by Smith et al. (1995) andWhite et al. (1998). HaCaT cells, an
immortalized human keratinocyte cell line, which were kindly
provided by N. Fusenig, were grown to conﬂuence in Dulbecco's
modiﬁed Eagle's medium supplemented with 10% fetal bovine serum,
2 mM glutamine, 1 mM pyruvate, 100 U/ml penicillin, and 100 μg/ml
streptomycin and then seeded 50,000 cells/well in a 24-well plate.After 48h, cellswere subconﬂuent. Themediumwas aspirated from the
HaCaT cells and Optiprep-fractionated CVPs were diluted either 1:20
for 10-day CVPs or 1:1000 for 20-day CVPs in HaCaT media and then
inoculated to the HaCaTs in a total volume of 0.5 ml. One well on each
plate received0.5ml ofmediumwithout virus as a negative control. The
cells were incubatedwith the virus for 48 h at 37 °C. The ability to infect
HaCaT cells after 48 h of incubation was determined by the presence of
the spliced HPV16 E1^ E4 mRNA species (Smith et al., 1995 and White
et al., 1998).mRNAwas puriﬁed from the infected cells using themRNA
capture kit (Roche Molecular Biochemicals, Indianapolis, IN). Brieﬂy,
themediumwasaspirated fromthe cells and the cellswerewashed two
times with 0.5 ml ice cold 1× PBS. The ﬁnal PBS wash was aspirated
from the cells and 0.25 ml lysis buffer was added to each well. The cell
lysates were removed from the wells and sonicated for 2 min in a cup
horn sonicator on ice. Fourmicroliters of 1:20 diluted biotinylated oligo
dTwas added to each lysate. The samples were incubated for 10min at
42 °C. Fifty microliters of the lysate was transferred to a streptavidin-
coated PCR tube and incubated for 3 min at 37 °C. The RNA captured in
the tubes was washed three times with 200 μl of wash buffer and
subsequently used in a RT reaction utilizing reagents from the First
Strand cDNA kit (Roche Molecular Biochemicals). The cDNA was then
used for nested PCR to detect theHPV16E1E4 cDNA. Forty cycles of PCR
was performed on the cDNAusing 5′TGGAAGACCTGTTAATGGGCACA3′
as the forward primer (located at nucleotide position 797–820 in the
HPV16 genome) and 5′ GTTACTATTACAGTTAATCCGTCC3′ (located at
nucleotides 3584–3607 in the HPV16 genome) as the reverse primer.
Ten percent of the ﬁrst PCRmixture was used as template for 40 cycles
of nested ampliﬁcation utilizing 5′GGAATTGTGTGCCCCATCTGTTC3′
(located at nucleotide position 823–845 in the HPV16 genome) as the
forward nested primer and 5′GCAACAACTTAGTGGTGTGGC3′ (located
at nucleotide position 3507–3527 in the HPV16 genome) as the reverse
nested primer. An additional set of primers speciﬁc for β-actin was
included in the PCR mixture as a control for mRNA detection. The
forward primer for the ﬁrst reaction was 5′GAACCCCAAGGC-
CAACCGCGA3′ and the reverse primer was 5′CCACACAGAG-
TACTTGCGCTCAGG3′. The forward primer for the nested reaction was
5′GATGACCCAGATCATGTTTG3′ and the reverse primer was 5′GGAG-
CATGATCTTGATCTTC3′. All PCR reactions contained 10 mM Tris–HCl,
pH 8.3, 50 mM KCl, 2.5 mM MgCl2, 200 μM dNTPs, 125 ng of each
forward and reverse primer, and 2.5 U of Taq polymerase (Fisher
Scientiﬁc). The temperature proﬁle for the ﬁrst reaction was 95 °C for
5 min, followed by 40 cycles of 95 °C for 30 s, 60 °C for 30 s, 72 °C for
1 min with a ﬁnal 10-min extension at 72 °C. The temperature proﬁle
for the second reaction was 95 °C for 5 min, followed by 40 cycles of
95 °C for 30 s, 60 °C for 30 s, 72 °C for 30 s with a ﬁnal 10-min extension
at 72 °C. All PCR products were visualized by electrophoresis in a 2%
agarose–ethidium bromide gel.
Quantitative RT-qPCR infectivity assays
As in the endpoint RT-PCR infectivity assay, HaCaT cells were
grown to conﬂuence in Dulbecco's modiﬁed Eagle's medium supple-
mented with 10% fetal bovine serum, 2 mM glutamine, 1 mM
pyruvate, 100 U/ml penicillin, and 100 μg/ml streptomycin and
seeded 50,000 cells/well in 24-well plates. CVPs were diluted with
cell culture medium to a total volume of 0.5 ml. For neutralization
assays, 1:100 dilutions of anti-P14/27 #2, anti-P56/75 #1, #S910-1,
or RG-1 were added to the mixture above and incubated for 1 h at
37 °C prior to infection (Gambhira et al., 2007; Kondo et al., 2007).
Medium was aspirated from HaCaT cells and 0.5 ml of diluted CVPs
was added per well. One well on each plate received 0.5 ml of medium
without virus as a negative control. The cells were incubated with the
virus for 48 h at 37 °C. mRNA was harvested with the SurePrep
TrueTotal RNA Puriﬁcation Kit (Fisher Scientiﬁc). DNA contamination
of columns was insigniﬁcant in that the optional on-column DNase-I
treatment of extracted mRNA had no effect on downstream signal.
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control target was performed using a duplex format in 0.2 ml, 96-
well PCR plates (BIO-RAD) with a total reaction volume of 25 μl. All
reactions containing RNAs from virus-infected cells were performed
in duplicate or triplicate. Reverse transcription and quantitative PCR
were performed in the same closed tube with approximately 250 ng
of total RNA per reaction using the Quantitect Probe RT-PCR Kit
(Qiagen). HPV16 E1^E4 primers used were the splice-site straddling,
5′GCTGATCCTGCAAGCAACGAAGTATC3′ (nt 868-3372) and 5′GGA-
TTGGAGCACTGTCCACTGAG 3′ (nt 3535-3557) at ﬁnal concentra-
tions of 4 μM. A ﬂuorogenic, dual-labeled, HPV16 E1^E4 probe of 5′
6-FAM CACCGGAAACCCCTGCCACACCACTAAG BHQ-1 3′ (nt 3493-
3520) was utilized at a ﬁnal concentration of 0.2 μM to detect E1^E4
cDNA. Primers and probe were developed using Gene Link Software:
OligoAnalyzer 1.2, and OligoExplorer 1.2. TATA-binding protein
(TBP) amplicons were created using primers 5′ CACGGCACTGAT-
TTTCAGTTCT 3′ (nt 627-648) and 5′ TTCTTGCTGCCAGTCTGGACT 3′
(nt 706-686) at ﬁnal concentrations of 0.125 μM. TBP amplicons
were detected by the ﬂuorogenic TaqManTM probe 5′HEX TGTGCA-
CAGGAGCCAAGAGTGAAGA BHQ-13′ used at 0.2 μM. TBP primer
sequences were obtained from those previously described (Culp and
Christensen, 2003). All primers were synthesized by Integrated DNA
Technologies (Coralville, IA). All QRT-PCR reactions were performed
using the iQ5 (BIO-RAD). Cycling conditions were 50 °C for 30 min
(reverse transcription) and 95 °C for 15 min, followed by 42 cycles of
94 °C for 15 s and 54.5 °C for 1 min. Ampliﬁcation efﬁciencies of each
primer set was 93% for E1^E4 and 97% for TBP. Relative quantities of
viral target cDNA were determined using REST software.
qPCR-based DNA encapsidation assay
To detect endonuclease-resistant genomes in crude virus preps or
Optiprep fractions, only benzonase-treated virus preps were utilized
so that all non-encapsidated genomes were digested. To break up any
aggregated virions within samples, virus preps and fractions were
sonicated utilizing aMisonix 3000 sonicator for 30 s at a power setting
of 6.5. To release all encapsidated viral genomes, 10 μl sonicated virus
prep or 20 μl Optiprep fraction was added to 2 μl Proteinase K, 10 μl
10% SDS, 2 μl pCMV-GFP (140 ng/μl) carrier DNA, and brought up to
200 μl with Hirt buffer. Tubes were rotated at 37 °C for 2 h. Tubes were
spiked with 12 μl 2-Mercaptoethanol, vortexed for 30 s, and followed
by 10 min of incubation in boiling water. Immediately, an equal
amount of phenol–chloroform–isoamyl alcohol (25:24:1) was added
and the mixture was extracted for the aqueous phase. An equal
amount of chloroformwas added and again extracted for the aqueous
phase. DNA was EtOH precipitated overnight at −20 °C. After
centrifugation, the DNA pellet was washed with 70% EtOH and
resuspended in 20 μl TE overnight and was termed an endonuclease-
resistant viral genome prep. To detect viral genomes in the
endonuclease-resistant viral genome preps, a Qiagen Quantitect
SYBR Green PCR kit was utilized. Ampliﬁcation of the viral target
was performed in 0.2 ml, 96-well PCR plates (BIO-RAD) with a total
reaction volume of 25 μl. l μl of each endonuclease-resistant viral
genome prep was analyzed in triplicate for each independent expe-
riment. Ampliﬁcation of HPV16 genomes was performed using 0.3 μM
5′CCATATAGACTATTGGAAACACATGCGCC3′ as the forward primer
(nt 2839–2868) and 0.3 μM 5′CGTTAGTTGCAGTTCAATTGCTTGTA-
ATGC3′ as the reverse primer (nt 2960–2989). Oligonucleotides were
synthesized by Integrated DNA Technologies (Coralville, IA). A
standard curve was generated by amplifying 1 μl aliquots of 104,
103, 102, and 101 serially diluted pBSHPV16 copy number controls.
Acceptable R2 values for standard curves were at or above 0.99. A Bio-
Rad iQ5 Multicolor Real-Time qPCR machine and software were
utilized for PCR ampliﬁcations and subsequent data analysis. The
PCR thermocycling proﬁle was as follows: 15-min hot-start at 95 °C,
followed by 40 cycles at 15 s at 94 °C, 30 s at 52 °C, and 30 s at 72 °C.Data analysis commenced during the extension phase. Melt curve
analyses were performed for all SYBR Green PCR ampliﬁcations to
verify speciﬁcity of the reaction. Melt curves and ﬁrst derivative melt
curves were run immediately after the last PCR cycle. Melt curves
were produced by plotting the ﬂuorescence intensity against tempe-
rature as the temperature was increased from 60 to 95 °C at 0.5 °C/s.
To further verify speciﬁcity of the reaction, qPCR products were
visualized via gel electrophoresis for single products of expected size.
Calculation of the exact number of endonuclease-resistant viral
genomes per 3-raft virus prep was determined by comparing expe-
rimental values to the number of actual pBSHPV16 copies within the
serially diluted copy number controls.
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